Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Read more here.

With a technique called cell painting, Recursion Pharmaceuticals is creating a really big picture of morphology of cells in the body. But that's just the beginning; the really hard part is knowing ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity.